Literature DB >> 11138611

Reference distributions for the positive acute phase serum proteins, alpha1-acid glycoprotein (orosomucoid), alpha1-antitrypsin, and haptoglobin: a practical, simple, and clinically relevant approach in a large cohort.

R F Ritchie1, G E Palomaki, L M Neveux, O Navolotskaia, T B Ledue, W Y Craig.   

Abstract

Most clinical conditions are accompanied by corresponding changes in serum levels of some, if not all, of the acute phase proteins. While conditions that affect the acute phase proteins are usually inflammatory in nature, non-inflammatory conditions also can cause changes (e.g., malnutrition, some malignancies without secondary inflammation, and genetic polymorphism). Only after the confounding effects of non-inflammatory conditions are taken into account can these measurements be used to detect and stage the inflammatory process and to evaluate the impact of treatment. In this third article in a series, reference ranges for serum levels for three of the acute phase proteins that increase during inflammation are examined: alpha1-acid glycoprotein (orosomucoid), alpha-antitrypsin, and haptoglobin. The study is based on a cohort of 55,199 Caucasian individuals from northern New England, tested in our laboratory between 1994 and 1999. Measurements were standardized against CRM 470 (RPPHS) and analyzed using a previously described statistical approach. Individuals with unequivocal laboratory evidence of inflammation (C-reactive protein of 10 mg/l or higher) were excluded. Levels of a,-acid glycoprotein changed little during life and between the sexes. Levels of alpha1-antitrypsin varied somewhat by age, rising slightly beyond age 55; males followed a pattern similar to that for females. For this protein, it was necessary to apply two equations to describe the lower levels associated with certain phenotypes. Haptoglobin levels fell significantly during the first decade of life for both males and females and climbed thereafter. Males and females displayed a similar pattern. When values were expressed as multiples of the age- and gender-specific median levels, the resulting distributions fitted a log-Gaussian distribution well over a broad range. When patient data are normalized in this manner, the distribution parameters can be used to assign a centile corresponding to an individual's measurement, thus simplifying interpretation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138611      PMCID: PMC6807811          DOI: 10.1002/1098-2825(20001212)14:6<284::aid-jcla7>3.0.co;2-u

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  20 in total

1.  [Sex-specific differences of serum proteins in adults and influence of oral hormonal contraceptives on serum protein composition].

Authors:  D Dotchev; N Liappis; H Hungerland
Journal:  Clin Chim Acta       Date:  1973-03-30       Impact factor: 3.786

2.  Concentration of serum prealbumin and retinol-binding proteins during pregnancy.

Authors:  G P Giacoia
Journal:  South Med J       Date:  1984-10       Impact factor: 0.954

3.  Serum protein pattern in normal pregnancy with special reference to acute-phase reactants.

Authors:  K Haram; K Augensen; S Elsayed
Journal:  Br J Obstet Gynaecol       Date:  1983-02

4.  Is immunochemical determination of haptoglobin phenotype dependent?

Authors:  I Valette; J Pointis; Y Rondeau; M Waks; R Engler
Journal:  Clin Chim Acta       Date:  1979-11-15       Impact factor: 3.786

Review 5.  Anaemia and iron deficiency in athletes. Practical recommendations for treatment.

Authors:  J C Chatard; I Mujika; C Guy; J R Lacour
Journal:  Sports Med       Date:  1999-04       Impact factor: 11.136

6.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.

Authors:  P M Ridker; M Cushman; M J Stampfer; R P Tracy; C H Hennekens
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

7.  Total serum protein and serum protein fractions in depression: relationships to depressive symptoms and glucocorticoid activity.

Authors:  M Maes; A Wauters; H Neels; S Scharpé; A Van Gastel; P D'Hondt; D Peeters; P Cosyns; R Desnyder
Journal:  J Affect Disord       Date:  1995-04-16       Impact factor: 4.839

8.  Re-evaluation of the haptoglobin reference values with the radial immunodiffusion technique.

Authors:  J Schrijver; J M Van Rijn; W H Schreurs
Journal:  Clin Biochem       Date:  1984-08       Impact factor: 3.281

9.  Salicylate-induced increases in free triiodothyronine in human serum. Evidence of inhibition of triiodothyronine binding to thyroxine-binding globulin and thyroxine-binding prealbumin.

Authors:  P R Larsen
Journal:  J Clin Invest       Date:  1972-05       Impact factor: 14.808

Review 10.  Transthyretin (prealbumin) in health and disease: nutritional implications.

Authors:  Y Ingenbleek; V Young
Journal:  Annu Rev Nutr       Date:  1994       Impact factor: 11.848

View more
  9 in total

1.  Urine proteomics for profiling of human disease using high accuracy mass spectrometry.

Authors:  Alex Kentsis; Flavio Monigatti; Kevin Dorff; Fabien Campagne; Richard Bachur; Hanno Steen
Journal:  Proteomics Clin Appl       Date:  2009-09-01       Impact factor: 3.494

2.  Reference distributions for apolipoproteins AI and B and the apolipoprotein B/AI ratios: a practical and clinically relevant approach in a large cohort.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Thomas B Ledue; Wendy Y Craig; Santica Marcovina; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

3.  Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome.

Authors:  Sabina Janciauskiene; Torsten Krakau
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

4.  Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia; Thomas B Ledue; Wendy Y Craig
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

5.  Reference distributions for alpha2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia; Thomas B Ledue; Wendy Y Craig
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

6.  A genome-wide association study identifies rs2000999 as a strong genetic determinant of circulating haptoglobin levels.

Authors:  Philippe Froguel; Ndeye Coumba Ndiaye; Amélie Bonnefond; Nabila Bouatia-Naji; Aurélie Dechaume; Gérard Siest; Bernard Herbeth; Mario Falchi; Leonardo Bottolo; Rosa-Maria Guéant-Rodriguez; Cécile Lecoeur; Michel R Langlois; Yann Labrune; Aimo Ruokonen; Said El Shamieh; Maria G Stathopoulou; Anita Morandi; Claudio Maffeis; David Meyre; Joris R Delanghe; Peter Jacobson; Lars Sjöström; Lena M S Carlsson; Andrew Walley; Paul Elliott; Marjo-Riita Jarvelin; George V Dedoussis; Sophie Visvikis-Siest
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

7.  In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis.

Authors:  Anne Plum; Lisbeth Bjerring Jensen; Jesper Bøggild Kristensen
Journal:  J Pharm Sci       Date:  2013-07-12       Impact factor: 3.534

8.  Individual variation in levels of haptoglobin-related protein in children from Gabon.

Authors:  Heather J Imrie; Freya J I Fowkes; Florence Migot-Nabias; Adrian J F Luty; Philippe Deloron; Stephen L Hajduk; Karen P Day
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

9.  Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

Authors:  Olivier Deckmyn; Thierry Poynard; Pierre Bedossa; Valérie Paradis; Valentina Peta; Raluca Pais; Vlad Ratziu; Dominique Thabut; Angelique Brzustowski; Jean-François Gautier; Patrice Cacoub; Dominique Valla
Journal:  Biomedicines       Date:  2022-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.